Photo of Tom Powles taken from bartscancer.london
May 28, 2024, 14:33
Tom Powles: Final results for axitinib/avelumab in 1st line RCC at ASCO24
Tom Powles, Director of Barts Cancer Center, shared on X:
“Final results for axitinib/avelumab in 1st line RCC at ASCO24.
It wasn’t initially backed due to no significant OS (unlike PD1 combos). .
HRs for the PD-1 combos have drifted (0.5s to 0.7s) but remain significant, unlike axi/avelumab (OS HR0.88). PD1 combos remain the stand of care.”
Source: Tom Powles/X
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Nov 20, 2024, 01:07
Nov 20, 2024, 01:00
Nov 20, 2024, 00:40
Nov 20, 2024, 00:31
Nov 20, 2024, 00:29